'Toxic drug' presentation slideshows

Spotlight Case

Spotlight Case. One Toxic Drug Is Not Like Another. Source and Credits. This presentation is based on the February 2011 AHRQ WebM&M Spotlight Case See the full article at http://webmm.ahrq.gov CME credit is available Commentary by: Eric S. Holmboe, MD, American Board of Internal Medicine

309 views • 20 slides

Toxic Epidermal Necrolysis

1.08k views • 13 slides

FDA Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer

"Sacituzumab govitecan, the most advanced candidate in Immunomedics, is a novel first-in-class ADC drug consisting of anti-TROP-2 monoclonal antibody and cytotoxic SN-38. In contrast, Immunomedics uses the moderately toxic drug SN-38 instead of the super cytotoxic drug calicheamicin. "

134 views • 2 slides

FDA Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer

Sacituzumab govitecan, the most advanced candidate in Immunomedics, is a novel first-in-class ADC drug consisting of anti-TROP-2 monoclonal antibody and cytotoxic SN-38. In contrast, Immunomedics uses the moderately toxic drug SN-38 instead of the super cytotoxic drug calicheamicin. Learn more from https://www.creative-biolabs.com/blog/adc/fda-grants-priority-review-for-sacituzumab-govitecan-triple-negative-breast-cancer/

26 views • 2 slides